Navigation Links
Cell receptor has proclivity for T helper 9 cells, airway inflammation

BOSTON, MAA research team led by Xian Chang Li, MD, PhD, Brigham and Women's Hospital (BWH) Transplantation Research Center, has shed light on how a population of lymphocytes, called CD4+ T cells, mature into various subsets of adult T helper cells. In particular, the team uncovered that a particular cell surface molecule, known as OX40, is a powerful inducer of new T helper cells that make copious amounts of interleukin-9 (IL-9) (and therefore called TH9 cells) in vitro; such TH9 cells are responsible for ongoing inflammation in the airways in the lungs in vivo.

The study will be published online in Nature Immunology on July 29, 2012.

In their studies, the researchers found that mice with hyper-active OX40 activities had signs of tissue inflammation, particularly in tissues lining the airway. A high amount of cellsas much as 30 percentin these tissues were mucin-producing cells. Mucin-producing cells produce gel-like secretions that, when combined with other secretions, can form mucus or saliva.

The results mirrored previous studies of mice who over expressed IL-9 in the lung airways. Results from additional experiments confirmed that OX40 triggers both TH9 cell and IL-9 production, thereby leading to airway inflammation.

"These findings may have broad impact on how to treat chronic inflammation, such as allergic inflammation and chronic allograft rejection after transplantation, since the inflammatory texture organized by TH9 cells tends to be different and ongoing." said Li.

In addition to this translational finding, Li and his team made strides in better understanding OX40's role in the molecular mechanisms of the pathway responsible for TH9 cell induction.

According to Li, the revelation that OX40 promotes TH9 cells through TRAF6 (a protein that mediates cell signaling) and the activation of a non-canonical NF-kB pathway will point to new opportunities in drug discovery and development in treatment of TH9-related diseases.

Contact: Marjorie Montemayor-Quellenberg
Brigham and Women's Hospital

Related biology news :

1. Measuring progesterone receptor expression to improve hormone-receptor-positive cancer management
2. G protein-coupled receptor mediates the action of castor oil
3. BUSM study identifies receptors role in regulating obesity, type 2 diabetes
4. Invisible helpers: How probiotic bacteria protect against inflammatory bowel diseases
5. Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
6. Cystic fibrosis makes airways more acidic, reduces bacterial killing
7. New proteins to clear the airways in cystic fibrosis and COPD
8. Weight loss led to reduction in inflammation
9. Modest alcohol intake associated with less inflammation in patients with common liver disease
10. Intestinal bacteria produce neurotransmitter, could play role in inflammation
11. Omega-3 lowers inflammation in overweight older adults
Post Your Comments:
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
Breaking Biology Technology: